Cargando…
Trastuzumab for HER2-Positive Metastatic Breast Cancer: Clinical and Economic Considerations
Trastuzumab is a recombinant humanized monoclonal antibody that selectively targets the extra-cellular domain of the HER2 receptor. It was approved by the FDA in September 1998 as the first targeted therapy for HER2-positive metastatic breast cancer, and has since led to significant improvements in...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Libertas Academica
2012
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3327515/ https://www.ncbi.nlm.nih.gov/pubmed/22518088 http://dx.doi.org/10.4137/CMO.S6460 |